Transparent information on the evidence supporting global recommendations on pediatric medicines should be easily accessible in order to help policy makers decide on what drugs to include in their national drug lists, write international experts from Ghana and the UK in this week's PLOS Medicine.
The authors, led by David Sinclair from the Liverpool School of Tropical Medicine, report the experiences of the Ghana National Drugs Programme as it reviewed the international evidence base for five priority pediatric medicines* in order to decide whether or not to include them in Ghana's essential medicines list.
According to the authors, applying the global recommendations to Ghana was not straightforward for any of the five medicines, despite high quality evidence of important clinical benefits, because of the unproven effect of the drugs in African settings and the scant information on cost effectiveness and the supply chain.
They say: "This project demonstrates why global recommendations should be presented alongside transparent descriptions of the evidence base, allowing policy makers to identify where, when, and how the interventions have been evaluated, and any factors limiting wider applicability."
The authors argue: "In addition, for interventions where feasibility and affordability are likely to vary from setting to setting, the World Health Organization could further assist national decision-makers by providing implementation guidance on the assessment of health system implications, training and education requirements, and country level cost analyses."
They conclude: "As many policy questions are relevant across sub-Saharan Africa, and policy makers are likely to encounter recurrent problems, we encourage regional collaboration on health technology assessment, and sharing of information and resources."